Interactions Between Galectin-3 and Cardiovascular Risk in Patients With Chronic Lymphocytic Leukemia in Remission: Results of 3-Year Prospective Study

Current issues in pharmacy and medicine: science and practice
doi 10.14739/2409-2932.2018.3.145251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Zaporozhye State Medical University

Related search

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Results of Research of Galectin-3 and Thyroglobulin in Patients With Thyroid Nodules

Grekov's Bulletin of Surgery
2015English

Lymphocyte Activation Gene 3: A Novel Therapeutic Target in Chronic Lymphocytic Leukemia

Haematologica
Hematology
2017English

Early Treatment With FCR Versus Watch and Wait in Patients With Stage Binet a High-Risk Chronic Lymphocytic Leukemia (CLL): A Randomized Phase 3 Trial

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2020English

3-Year Results of Transvaginal Cystocele Repair With Transobturator Four-Arm Mesh: A Prospective Study of 105 Patients

Arab Journal of Urology
Urology
2014English

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Circulating VE-cadherin in Patients With Controlled Chronic Lymphocytic Leukemia

Pathologia
2014English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

The Role of Galectin-3 in Heart Failure and Cardiovascular Disease

Clinical and Experimental Pharmacology and Physiology
PhysiologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy